Our study shows that inhibition of NF-κB in the lungs significantly reduced Acta2 expression in BLM treated IKBM mice indicating an effective therapeutic approach for the treatment of pulmonary fibrosis. This evidence concerns the gene NFKB1 and pulmonary fibrosis.